- Profile
- prev
- next
General
-
Headquarters
California, United States
-
Founders & Team
Tom Benson
-
Year Founded
2018
-
Company type
Private company
-
Funding stage
Pre-seed
-
Investors
Longevitytech.fund
Technical Details
-
Aging Target
Mitochondrial dysfunction
-
Product modality
cell therapy, mitochondrial transplant
About
Whole-body mitochondrial transfusion. Addressing Alzheimer's, Parkinson's, heart disease, sarcopenia, and other diseases of aging.
The Problem
Dozens of diseases are based partially, or entirely, on the decline of mitochondrial function as we age. How can we help mitochondria - one of the most powerful and perfectly optimized systems in biology - to become healthier?
The Solution
With whole-body mitochondrial transfusion, we grow huge numbers of your "young" mitochondria in external bioreactors, then transfuse them into your body where they are taken up by cells and immediately start boosting ATP production, enabling cells to regenerate to a more youthful state.
This has already been successfully tested on human patients in compassionate-use cases of specific mitochondrial dysfunction.